nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP3A4—bone cancer	0.886	1	CbGaD
Methazolamide—Acetazolamide—CYP3A4—bone cancer	0.00704	1	CrCbGaD
Methazolamide—Hepatic insufficiency—Methotrexate—bone cancer	0.00617	0.0787	CcSEcCtD
Methazolamide—CYP2E1—Felbamate Metabolism—CYP3A4—bone cancer	0.00269	0.094	CbGpPWpGaD
Methazolamide—CA9—HIF-1-alpha transcription factor network—CITED2—bone cancer	0.00229	0.0799	CbGpPWpGaD
Methazolamide—Appetite absent—Methotrexate—bone cancer	0.00192	0.0245	CcSEcCtD
Methazolamide—Body temperature increased—Carboplatin—bone cancer	0.00167	0.0213	CcSEcCtD
Methazolamide—Polyuria—Cisplatin—bone cancer	0.00144	0.0183	CcSEcCtD
Methazolamide—Bone marrow depression—Methotrexate—bone cancer	0.00141	0.018	CcSEcCtD
Methazolamide—Haemolytic anaemia—Cisplatin—bone cancer	0.0014	0.0178	CcSEcCtD
Methazolamide—Bone marrow depression—Epirubicin—bone cancer	0.00132	0.0169	CcSEcCtD
Methazolamide—Bone marrow depression—Doxorubicin—bone cancer	0.00122	0.0156	CcSEcCtD
Methazolamide—Glycosuria—Epirubicin—bone cancer	0.0011	0.0141	CcSEcCtD
Methazolamide—Blood disorder—Epirubicin—bone cancer	0.00107	0.0136	CcSEcCtD
Methazolamide—Pancytopenia—Cisplatin—bone cancer	0.00104	0.0132	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—bone cancer	0.00102	0.013	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—bone cancer	0.000989	0.0126	CcSEcCtD
Methazolamide—Melaena—Methotrexate—bone cancer	0.000932	0.0119	CcSEcCtD
Methazolamide—Aplastic anaemia—Methotrexate—bone cancer	0.000896	0.0114	CcSEcCtD
Methazolamide—CYP2E1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000885	0.0309	CbGpPWpGaD
Methazolamide—Melaena—Epirubicin—bone cancer	0.000872	0.0111	CcSEcCtD
Methazolamide—Urine output increased—Methotrexate—bone cancer	0.000862	0.011	CcSEcCtD
Methazolamide—Aplastic anaemia—Epirubicin—bone cancer	0.000838	0.0107	CcSEcCtD
Methazolamide—Tinnitus—Cisplatin—bone cancer	0.000814	0.0104	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—bone cancer	0.000807	0.0103	CcSEcCtD
Methazolamide—Polyuria—Methotrexate—bone cancer	0.000789	0.0101	CcSEcCtD
Methazolamide—Photosensitivity—Methotrexate—bone cancer	0.000789	0.0101	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—bone cancer	0.000776	0.0099	CcSEcCtD
Methazolamide—Hepatic failure—Methotrexate—bone cancer	0.000771	0.00983	CcSEcCtD
Methazolamide—Photosensitivity—Epirubicin—bone cancer	0.000738	0.00942	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—bone cancer	0.000721	0.0092	CcSEcCtD
Methazolamide—Ill-defined disorder—Cisplatin—bone cancer	0.000705	0.009	CcSEcCtD
Methazolamide—Malaise—Cisplatin—bone cancer	0.000685	0.00875	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—bone cancer	0.000683	0.00872	CcSEcCtD
Methazolamide—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000683	0.0238	CbGpPWpGaD
Methazolamide—Leukopenia—Cisplatin—bone cancer	0.00068	0.00868	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—bone cancer	0.000667	0.00852	CcSEcCtD
Methazolamide—Convulsion—Cisplatin—bone cancer	0.000658	0.0084	CcSEcCtD
Methazolamide—Discomfort—Cisplatin—bone cancer	0.000639	0.00816	CcSEcCtD
Methazolamide—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000631	0.022	CbGpPWpGaD
Methazolamide—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000628	0.0219	CbGpPWpGaD
Methazolamide—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000624	0.00796	CcSEcCtD
Methazolamide—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000622	0.0217	CbGpPWpGaD
Methazolamide—Anaphylactic shock—Cisplatin—bone cancer	0.00062	0.00792	CcSEcCtD
Methazolamide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000595	0.0208	CbGpPWpGaD
Methazolamide—Anorexia—Cisplatin—bone cancer	0.000591	0.00755	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000584	0.00745	CcSEcCtD
Methazolamide—Pancytopenia—Methotrexate—bone cancer	0.000568	0.00725	CcSEcCtD
Methazolamide—Paraesthesia—Cisplatin—bone cancer	0.000557	0.00711	CcSEcCtD
Methazolamide—Photosensitivity reaction—Methotrexate—bone cancer	0.000546	0.00697	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00054	0.00689	CcSEcCtD
Methazolamide—Decreased appetite—Cisplatin—bone cancer	0.000539	0.00688	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Cisplatin—bone cancer	0.000535	0.00683	CcSEcCtD
Methazolamide—Drowsiness—Methotrexate—bone cancer	0.000534	0.00681	CcSEcCtD
Methazolamide—Pancytopenia—Epirubicin—bone cancer	0.000532	0.00679	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000529	0.00675	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—bone cancer	0.000511	0.00652	CcSEcCtD
Methazolamide—Feeling abnormal—Cisplatin—bone cancer	0.000511	0.00652	CcSEcCtD
Methazolamide—CYP2E1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00051	0.0178	CbGpPWpGaD
Methazolamide—Haematuria—Methotrexate—bone cancer	0.000509	0.00649	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—bone cancer	0.000499	0.00637	CcSEcCtD
Methazolamide—Agranulocytosis—Methotrexate—bone cancer	0.000498	0.00636	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000495	0.00632	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—bone cancer	0.000492	0.00628	CcSEcCtD
Methazolamide—Body temperature increased—Cisplatin—bone cancer	0.00049	0.00626	CcSEcCtD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000478	0.0167	CbGpPWpGaD
Methazolamide—Haematuria—Epirubicin—bone cancer	0.000476	0.00608	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—bone cancer	0.000473	0.00604	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—bone cancer	0.000466	0.00595	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—bone cancer	0.000462	0.0059	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000458	0.00585	CcSEcCtD
Methazolamide—Erythema multiforme—Methotrexate—bone cancer	0.000453	0.00578	CcSEcCtD
Methazolamide—Tinnitus—Methotrexate—bone cancer	0.000447	0.0057	CcSEcCtD
Methazolamide—Asthenia—Cisplatin—bone cancer	0.000445	0.00568	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—bone cancer	0.000441	0.00562	CcSEcCtD
Methazolamide—Agranulocytosis—Doxorubicin—bone cancer	0.000431	0.0055	CcSEcCtD
Methazolamide—CYP2E1—Xenobiotics—CYP3A4—bone cancer	0.000427	0.0149	CbGpPWpGaD
Methazolamide—Diarrhoea—Cisplatin—bone cancer	0.000424	0.00542	CcSEcCtD
Methazolamide—Erythema multiforme—Epirubicin—bone cancer	0.000424	0.00541	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—bone cancer	0.000418	0.00533	CcSEcCtD
Methazolamide—CYP2E1—Tamoxifen metabolism—CYP3A4—bone cancer	0.000411	0.0143	CbGpPWpGaD
Methazolamide—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00041	0.0143	CbGpPWpGaD
Methazolamide—Dysgeusia—Methotrexate—bone cancer	0.000408	0.00521	CcSEcCtD
Methazolamide—Vomiting—Cisplatin—bone cancer	0.000394	0.00503	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—bone cancer	0.000392	0.00501	CcSEcCtD
Methazolamide—Rash—Cisplatin—bone cancer	0.000391	0.00499	CcSEcCtD
Methazolamide—Dermatitis—Cisplatin—bone cancer	0.000391	0.00499	CcSEcCtD
Methazolamide—Ill-defined disorder—Methotrexate—bone cancer	0.000387	0.00494	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—bone cancer	0.000387	0.00494	CcSEcCtD
Methazolamide—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000386	0.0135	CbGpPWpGaD
Methazolamide—Dysgeusia—Epirubicin—bone cancer	0.000382	0.00488	CcSEcCtD
Methazolamide—CYP2E1—Metapathway biotransformation—CYP4V2—bone cancer	0.000381	0.0133	CbGpPWpGaD
Methazolamide—Malaise—Methotrexate—bone cancer	0.000376	0.0048	CcSEcCtD
Methazolamide—Vertigo—Methotrexate—bone cancer	0.000375	0.00478	CcSEcCtD
Methazolamide—Leukopenia—Methotrexate—bone cancer	0.000373	0.00476	CcSEcCtD
Methazolamide—Nausea—Cisplatin—bone cancer	0.000368	0.0047	CcSEcCtD
Methazolamide—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000362	0.0126	CbGpPWpGaD
Methazolamide—Ill-defined disorder—Epirubicin—bone cancer	0.000362	0.00462	CcSEcCtD
Methazolamide—Convulsion—Methotrexate—bone cancer	0.000361	0.00461	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—bone cancer	0.000354	0.00451	CcSEcCtD
Methazolamide—Malaise—Epirubicin—bone cancer	0.000352	0.00449	CcSEcCtD
Methazolamide—Discomfort—Methotrexate—bone cancer	0.000351	0.00448	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—bone cancer	0.000351	0.00447	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—bone cancer	0.000349	0.00446	CcSEcCtD
Methazolamide—Confusional state—Methotrexate—bone cancer	0.000343	0.00438	CcSEcCtD
Methazolamide—Anaphylactic shock—Methotrexate—bone cancer	0.00034	0.00434	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—bone cancer	0.000338	0.00432	CcSEcCtD
Methazolamide—CA9—Cellular responses to stress—BMI1—bone cancer	0.000337	0.0118	CbGpPWpGaD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000336	0.0117	CbGpPWpGaD
Methazolamide—Ill-defined disorder—Doxorubicin—bone cancer	0.000335	0.00428	CcSEcCtD
Methazolamide—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000329	0.0115	CbGpPWpGaD
Methazolamide—Discomfort—Epirubicin—bone cancer	0.000328	0.00419	CcSEcCtD
Methazolamide—Malaise—Doxorubicin—bone cancer	0.000326	0.00416	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—bone cancer	0.000324	0.00414	CcSEcCtD
Methazolamide—Anorexia—Methotrexate—bone cancer	0.000324	0.00414	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—bone cancer	0.000323	0.00413	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—bone cancer	0.000321	0.0041	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—bone cancer	0.000318	0.00406	CcSEcCtD
Methazolamide—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000317	0.0111	CbGpPWpGaD
Methazolamide—Convulsion—Doxorubicin—bone cancer	0.000313	0.00399	CcSEcCtD
Methazolamide—Paraesthesia—Methotrexate—bone cancer	0.000306	0.0039	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—bone cancer	0.000304	0.00388	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—bone cancer	0.000304	0.00387	CcSEcCtD
Methazolamide—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000303	0.0106	CbGpPWpGaD
Methazolamide—Somnolence—Methotrexate—bone cancer	0.000303	0.00386	CcSEcCtD
Methazolamide—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.0003	0.0105	CbGpPWpGaD
Methazolamide—Dyspepsia—Methotrexate—bone cancer	0.0003	0.00382	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—bone cancer	0.000297	0.00379	CcSEcCtD
Methazolamide—Decreased appetite—Methotrexate—bone cancer	0.000296	0.00378	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—bone cancer	0.000295	0.00376	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Methotrexate—bone cancer	0.000294	0.00375	CcSEcCtD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000294	0.0102	CbGpPWpGaD
Methazolamide—Fatigue—Methotrexate—bone cancer	0.000293	0.00374	CcSEcCtD
Methazolamide—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000291	0.0102	CbGpPWpGaD
Methazolamide—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000289	0.0101	CbGpPWpGaD
Methazolamide—Paraesthesia—Epirubicin—bone cancer	0.000286	0.00365	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—bone cancer	0.000283	0.00361	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—bone cancer	0.000281	0.00359	CcSEcCtD
Methazolamide—Feeling abnormal—Methotrexate—bone cancer	0.00028	0.00358	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—bone cancer	0.00028	0.00358	CcSEcCtD
Methazolamide—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000279	0.00974	CbGpPWpGaD
Methazolamide—Decreased appetite—Epirubicin—bone cancer	0.000277	0.00353	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Epirubicin—bone cancer	0.000275	0.00351	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—bone cancer	0.000275	0.0035	CcSEcCtD
Methazolamide—Urticaria—Methotrexate—bone cancer	0.00027	0.00345	CcSEcCtD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00027	0.00943	CbGpPWpGaD
Methazolamide—Body temperature increased—Methotrexate—bone cancer	0.000269	0.00343	CcSEcCtD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000268	0.00934	CbGpPWpGaD
Methazolamide—Paraesthesia—Doxorubicin—bone cancer	0.000265	0.00338	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—bone cancer	0.000262	0.00335	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—bone cancer	0.000262	0.00334	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—bone cancer	0.000259	0.00331	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—bone cancer	0.000256	0.00327	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000254	0.00325	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—bone cancer	0.000254	0.00324	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—bone cancer	0.000253	0.00323	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—bone cancer	0.000252	0.00321	CcSEcCtD
Methazolamide—CA1—C-MYB transcription factor network—KIT—bone cancer	0.000248	0.00864	CbGpPWpGaD
Methazolamide—Asthenia—Methotrexate—bone cancer	0.000244	0.00312	CcSEcCtD
Methazolamide—Feeling abnormal—Doxorubicin—bone cancer	0.000243	0.0031	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—bone cancer	0.000234	0.00299	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—bone cancer	0.000233	0.00297	CcSEcCtD
Methazolamide—Diarrhoea—Methotrexate—bone cancer	0.000233	0.00297	CcSEcCtD
Methazolamide—CA14—Metabolism—NDUFA12—bone cancer	0.000232	0.0081	CbGpPWpGaD
Methazolamide—Asthenia—Epirubicin—bone cancer	0.000229	0.00292	CcSEcCtD
Methazolamide—CA5A—Metabolism—NDUFA12—bone cancer	0.000226	0.00789	CbGpPWpGaD
Methazolamide—CA6—Metabolism—NDUFA12—bone cancer	0.000226	0.00789	CbGpPWpGaD
Methazolamide—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000226	0.00789	CbGpPWpGaD
Methazolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000222	0.00774	CbGpPWpGaD
Methazolamide—CYP2E1—Tryptophan metabolism—CYP3A4—bone cancer	0.000219	0.00765	CbGpPWpGaD
Methazolamide—Diarrhoea—Epirubicin—bone cancer	0.000218	0.00278	CcSEcCtD
Methazolamide—Vomiting—Methotrexate—bone cancer	0.000216	0.00276	CcSEcCtD
Methazolamide—Rash—Methotrexate—bone cancer	0.000215	0.00274	CcSEcCtD
Methazolamide—Dermatitis—Methotrexate—bone cancer	0.000214	0.00274	CcSEcCtD
Methazolamide—Headache—Methotrexate—bone cancer	0.000213	0.00272	CcSEcCtD
Methazolamide—Asthenia—Doxorubicin—bone cancer	0.000211	0.0027	CcSEcCtD
Methazolamide—CA7—Metabolism—NDUFA12—bone cancer	0.000211	0.00737	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—NDUFA12—bone cancer	0.000211	0.00737	CbGpPWpGaD
Methazolamide—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000206	0.00719	CbGpPWpGaD
Methazolamide—Vomiting—Epirubicin—bone cancer	0.000203	0.00258	CcSEcCtD
Methazolamide—Nausea—Methotrexate—bone cancer	0.000202	0.00258	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—bone cancer	0.000202	0.00257	CcSEcCtD
Methazolamide—Rash—Epirubicin—bone cancer	0.000201	0.00256	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—bone cancer	0.000201	0.00256	CcSEcCtD
Methazolamide—Headache—Epirubicin—bone cancer	0.0002	0.00255	CcSEcCtD
Methazolamide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000196	0.00685	CbGpPWpGaD
Methazolamide—CA12—Metabolism—NDUFA12—bone cancer	0.000196	0.00683	CbGpPWpGaD
Methazolamide—CA14—Metabolism—NT5C3A—bone cancer	0.000192	0.00671	CbGpPWpGaD
Methazolamide—Nausea—Epirubicin—bone cancer	0.000189	0.00241	CcSEcCtD
Methazolamide—CA1—C-MYB transcription factor network—PTGS2—bone cancer	0.000188	0.00656	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—NT5C3A—bone cancer	0.000188	0.00654	CbGpPWpGaD
Methazolamide—CA6—Metabolism—NT5C3A—bone cancer	0.000188	0.00654	CbGpPWpGaD
Methazolamide—Vomiting—Doxorubicin—bone cancer	0.000187	0.00239	CcSEcCtD
Methazolamide—Rash—Doxorubicin—bone cancer	0.000186	0.00237	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—bone cancer	0.000186	0.00237	CcSEcCtD
Methazolamide—Headache—Doxorubicin—bone cancer	0.000185	0.00236	CcSEcCtD
Methazolamide—CA9—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000181	0.00631	CbGpPWpGaD
Methazolamide—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000177	0.00618	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000177	0.00616	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—NT5C3A—bone cancer	0.000175	0.00611	CbGpPWpGaD
Methazolamide—CA7—Metabolism—NT5C3A—bone cancer	0.000175	0.00611	CbGpPWpGaD
Methazolamide—Nausea—Doxorubicin—bone cancer	0.000175	0.00223	CcSEcCtD
Methazolamide—CYP2E1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000175	0.0061	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—EZH2—bone cancer	0.000164	0.00572	CbGpPWpGaD
Methazolamide—CA12—Metabolism—NT5C3A—bone cancer	0.000162	0.00566	CbGpPWpGaD
Methazolamide—CA4—Metabolism—NDUFA12—bone cancer	0.000156	0.00544	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NDUFA12—bone cancer	0.00015	0.00522	CbGpPWpGaD
Methazolamide—CYP2E1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000144	0.00501	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NDUFA12—bone cancer	0.000143	0.005	CbGpPWpGaD
Methazolamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000137	0.00477	CbGpPWpGaD
Methazolamide—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000135	0.00471	CbGpPWpGaD
Methazolamide—CA4—Metabolism—NT5C3A—bone cancer	0.000129	0.00451	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—GSTP1—bone cancer	0.000128	0.00446	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NDUFA12—bone cancer	0.000126	0.0044	CbGpPWpGaD
Methazolamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000126	0.00439	CbGpPWpGaD
Methazolamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000125	0.00435	CbGpPWpGaD
Methazolamide—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000124	0.00433	CbGpPWpGaD
Methazolamide—CA2—Metabolism—NT5C3A—bone cancer	0.000124	0.00433	CbGpPWpGaD
Methazolamide—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000123	0.00429	CbGpPWpGaD
Methazolamide—CA1—Metabolism—NT5C3A—bone cancer	0.000119	0.00415	CbGpPWpGaD
Methazolamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000111	0.00387	CbGpPWpGaD
Methazolamide—CA9—Metabolism—NT5C3A—bone cancer	0.000104	0.00365	CbGpPWpGaD
Methazolamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000102	0.00356	CbGpPWpGaD
Methazolamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000101	0.00353	CbGpPWpGaD
Methazolamide—CYP2E1—Tryptophan metabolism—MDM2—bone cancer	0.000101	0.00352	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.68e-05	0.00338	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—CDK4—bone cancer	9.26e-05	0.00323	CbGpPWpGaD
Methazolamide—CA14—Metabolism—ENO2—bone cancer	8.43e-05	0.00294	CbGpPWpGaD
Methazolamide—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.35e-05	0.00291	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—ENO2—bone cancer	8.21e-05	0.00287	CbGpPWpGaD
Methazolamide—CA6—Metabolism—ENO2—bone cancer	8.21e-05	0.00287	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—RB1—bone cancer	8.05e-05	0.00281	CbGpPWpGaD
Methazolamide—CA14—Metabolism—DHFR—bone cancer	7.82e-05	0.00273	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—ENO2—bone cancer	7.67e-05	0.00267	CbGpPWpGaD
Methazolamide—CA7—Metabolism—ENO2—bone cancer	7.67e-05	0.00267	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—CYP3A4—bone cancer	7.63e-05	0.00266	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—DHFR—bone cancer	7.62e-05	0.00266	CbGpPWpGaD
Methazolamide—CA6—Metabolism—DHFR—bone cancer	7.62e-05	0.00266	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—CYP3A4—bone cancer	7.53e-05	0.00263	CbGpPWpGaD
Methazolamide—CA14—Metabolism—GNA11—bone cancer	7.31e-05	0.00255	CbGpPWpGaD
Methazolamide—CA6—Metabolism—GNA11—bone cancer	7.12e-05	0.00248	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—GNA11—bone cancer	7.12e-05	0.00248	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—DHFR—bone cancer	7.11e-05	0.00248	CbGpPWpGaD
Methazolamide—CA7—Metabolism—DHFR—bone cancer	7.11e-05	0.00248	CbGpPWpGaD
Methazolamide—CA12—Metabolism—ENO2—bone cancer	7.1e-05	0.00248	CbGpPWpGaD
Methazolamide—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	7.01e-05	0.00245	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—MDM2—bone cancer	6.86e-05	0.00239	CbGpPWpGaD
Methazolamide—CA7—Metabolism—GNA11—bone cancer	6.65e-05	0.00232	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—GNA11—bone cancer	6.65e-05	0.00232	CbGpPWpGaD
Methazolamide—CA14—Metabolism—CYP3A4—bone cancer	6.62e-05	0.00231	CbGpPWpGaD
Methazolamide—CA12—Metabolism—DHFR—bone cancer	6.59e-05	0.0023	CbGpPWpGaD
Methazolamide—CYP2E1—Biological oxidations—GSTP1—bone cancer	6.53e-05	0.00228	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—CYP3A4—bone cancer	6.46e-05	0.00225	CbGpPWpGaD
Methazolamide—CA6—Metabolism—CYP3A4—bone cancer	6.46e-05	0.00225	CbGpPWpGaD
Methazolamide—CYP2E1—Metapathway biotransformation—GSTP1—bone cancer	6.44e-05	0.00225	CbGpPWpGaD
Methazolamide—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.39e-05	0.00223	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GNA11—bone cancer	6.16e-05	0.00215	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—CYP3A4—bone cancer	6.03e-05	0.0021	CbGpPWpGaD
Methazolamide—CA7—Metabolism—CYP3A4—bone cancer	6.03e-05	0.0021	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—JUN—bone cancer	5.97e-05	0.00208	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—CYP3A4—bone cancer	5.89e-05	0.00205	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	5.81e-05	0.00203	CbGpPWpGaD
Methazolamide—CA14—Metabolism—GSTP1—bone cancer	5.67e-05	0.00198	CbGpPWpGaD
Methazolamide—CA4—Metabolism—ENO2—bone cancer	5.66e-05	0.00198	CbGpPWpGaD
Methazolamide—CA12—Metabolism—CYP3A4—bone cancer	5.58e-05	0.00195	CbGpPWpGaD
Methazolamide—CA6—Metabolism—GSTP1—bone cancer	5.52e-05	0.00193	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—GSTP1—bone cancer	5.52e-05	0.00193	CbGpPWpGaD
Methazolamide—CA2—Metabolism—ENO2—bone cancer	5.43e-05	0.00189	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—CYP3A4—bone cancer	5.42e-05	0.00189	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.37e-05	0.00187	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	5.34e-05	0.00186	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.3e-05	0.00185	CbGpPWpGaD
Methazolamide—CA4—Metabolism—DHFR—bone cancer	5.26e-05	0.00183	CbGpPWpGaD
Methazolamide—CA1—Metabolism—ENO2—bone cancer	5.21e-05	0.00182	CbGpPWpGaD
Methazolamide—CA7—Metabolism—GSTP1—bone cancer	5.15e-05	0.0018	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—GSTP1—bone cancer	5.15e-05	0.0018	CbGpPWpGaD
Methazolamide—CA2—Metabolism—DHFR—bone cancer	5.04e-05	0.00176	CbGpPWpGaD
Methazolamide—CYP2C19—Biological oxidations—GSTP1—bone cancer	5.04e-05	0.00176	CbGpPWpGaD
Methazolamide—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	4.97e-05	0.00173	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GNA11—bone cancer	4.91e-05	0.00171	CbGpPWpGaD
Methazolamide—CA1—Metabolism—DHFR—bone cancer	4.83e-05	0.00169	CbGpPWpGaD
Methazolamide—CA12—Metabolism—GSTP1—bone cancer	4.78e-05	0.00167	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GNA11—bone cancer	4.71e-05	0.00164	CbGpPWpGaD
Methazolamide—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	4.68e-05	0.00163	CbGpPWpGaD
Methazolamide—CYP2D6—Biological oxidations—GSTP1—bone cancer	4.63e-05	0.00162	CbGpPWpGaD
Methazolamide—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.59e-05	0.0016	CbGpPWpGaD
Methazolamide—CA9—Metabolism—ENO2—bone cancer	4.58e-05	0.0016	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NDUFA12—bone cancer	4.58e-05	0.0016	CbGpPWpGaD
Methazolamide—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	4.57e-05	0.00159	CbGpPWpGaD
Methazolamide—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.53e-05	0.00158	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GNA11—bone cancer	4.51e-05	0.00157	CbGpPWpGaD
Methazolamide—CA4—Metabolism—CYP3A4—bone cancer	4.45e-05	0.00155	CbGpPWpGaD
Methazolamide—CA2—Metabolism—CYP3A4—bone cancer	4.27e-05	0.00149	CbGpPWpGaD
Methazolamide—CA9—Metabolism—DHFR—bone cancer	4.25e-05	0.00148	CbGpPWpGaD
Methazolamide—CA1—Metabolism—CYP3A4—bone cancer	4.09e-05	0.00143	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GNA11—bone cancer	3.97e-05	0.00138	CbGpPWpGaD
Methazolamide—CA9—Cellular responses to stress—TP53—bone cancer	3.94e-05	0.00137	CbGpPWpGaD
Methazolamide—CA4—Metabolism—GSTP1—bone cancer	3.81e-05	0.00133	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—NT5C3A—bone cancer	3.79e-05	0.00132	CbGpPWpGaD
Methazolamide—CA2—Metabolism—GSTP1—bone cancer	3.65e-05	0.00127	CbGpPWpGaD
Methazolamide—CA9—Metabolism—CYP3A4—bone cancer	3.6e-05	0.00126	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NDUFA12—bone cancer	3.53e-05	0.00123	CbGpPWpGaD
Methazolamide—CA1—Metabolism—GSTP1—bone cancer	3.5e-05	0.00122	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NDUFA12—bone cancer	3.25e-05	0.00113	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NDUFA12—bone cancer	3.22e-05	0.00112	CbGpPWpGaD
Methazolamide—CA9—Metabolism—GSTP1—bone cancer	3.08e-05	0.00107	CbGpPWpGaD
Methazolamide—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.03e-05	0.00106	CbGpPWpGaD
Methazolamide—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	2.99e-05	0.00104	CbGpPWpGaD
Methazolamide—CA14—Metabolism—PTGS2—bone cancer	2.94e-05	0.00102	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—NT5C3A—bone cancer	2.93e-05	0.00102	CbGpPWpGaD
Methazolamide—CA5A—Metabolism—PTGS2—bone cancer	2.86e-05	0.000998	CbGpPWpGaD
Methazolamide—CA6—Metabolism—PTGS2—bone cancer	2.86e-05	0.000998	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—NT5C3A—bone cancer	2.69e-05	0.000939	CbGpPWpGaD
Methazolamide—CA5B—Metabolism—PTGS2—bone cancer	2.67e-05	0.000932	CbGpPWpGaD
Methazolamide—CA7—Metabolism—PTGS2—bone cancer	2.67e-05	0.000932	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—NT5C3A—bone cancer	2.67e-05	0.000931	CbGpPWpGaD
Methazolamide—CA12—Metabolism—PTGS2—bone cancer	2.47e-05	0.000863	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NDUFA12—bone cancer	2.12e-05	0.000741	CbGpPWpGaD
Methazolamide—CA4—Metabolism—PTGS2—bone cancer	1.97e-05	0.000688	CbGpPWpGaD
Methazolamide—CA2—Metabolism—PTGS2—bone cancer	1.89e-05	0.00066	CbGpPWpGaD
Methazolamide—CA1—Metabolism—PTGS2—bone cancer	1.81e-05	0.000633	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—NT5C3A—bone cancer	1.76e-05	0.000614	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—ENO2—bone cancer	1.66e-05	0.000579	CbGpPWpGaD
Methazolamide—CA9—Metabolism—PTGS2—bone cancer	1.59e-05	0.000556	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—DHFR—bone cancer	1.54e-05	0.000538	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GNA11—bone cancer	1.44e-05	0.000502	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—CYP3A4—bone cancer	1.31e-05	0.000455	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—ENO2—bone cancer	1.28e-05	0.000447	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—DHFR—bone cancer	1.19e-05	0.000415	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—ENO2—bone cancer	1.18e-05	0.000411	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—ENO2—bone cancer	1.17e-05	0.000408	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—GSTP1—bone cancer	1.12e-05	0.00039	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GNA11—bone cancer	1.11e-05	0.000388	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—DHFR—bone cancer	1.09e-05	0.000381	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—DHFR—bone cancer	1.08e-05	0.000378	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GNA11—bone cancer	1.02e-05	0.000356	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GNA11—bone cancer	1.01e-05	0.000353	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—CYP3A4—bone cancer	1.01e-05	0.000351	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1e-05	0.00035	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—CYP3A4—bone cancer	9.26e-06	0.000323	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—CYP3A4—bone cancer	9.18e-06	0.00032	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.14e-06	0.000319	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—GSTP1—bone cancer	8.61e-06	0.000301	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—GSTP1—bone cancer	7.92e-06	0.000276	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—GSTP1—bone cancer	7.86e-06	0.000274	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—ENO2—bone cancer	7.71e-06	0.000269	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—DHFR—bone cancer	7.15e-06	0.000249	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GNA11—bone cancer	6.68e-06	0.000233	CbGpPWpGaD
Methazolamide—CYP2E1—Metabolism—PTGS2—bone cancer	5.78e-06	0.000202	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—GSTP1—bone cancer	5.18e-06	0.000181	CbGpPWpGaD
Methazolamide—CYP2C19—Metabolism—PTGS2—bone cancer	4.46e-06	0.000156	CbGpPWpGaD
Methazolamide—CYP2D6—Metabolism—PTGS2—bone cancer	4.1e-06	0.000143	CbGpPWpGaD
Methazolamide—CYP2C9—Metabolism—PTGS2—bone cancer	4.07e-06	0.000142	CbGpPWpGaD
Methazolamide—CYP3A4—Metabolism—PTGS2—bone cancer	2.68e-06	9.36e-05	CbGpPWpGaD
